Clinical Trial Update: Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial update on once-daily targeted IV busulfan as part of reduced-toxicity conditioning for patients with refractory lymphomas undergoing allogeneic tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Busulfex (busulfan)

Snippet

Sponsor: West Virginia University | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-13